AV411

DRUG3 trials

Sponsors

Cambridge University Hospitals NHS Foundation Trust and University of Cambridge, Avigen, New York State Psychiatric Institute

Conditions

Degenerative Cervical MyelopathyDiabetic NeuropathyOpioid-Related Disorders

Phase 1

Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain

CompletedNCT00576277

AvigenDiabetic Neuropathy

Start: 2006-09-30End: 2007-11-30Target: 36Updated: 2007-12-19

Phase 2

Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal

CompletedNCT00723177

New York State Psychiatric InstituteOpioid-Related Disorders

Start: 2008-10-31End: 2012-06-30Updated: 2016-12-05

Phase 3

Randomised Placebo-controlled Double Blind Clinical Trial in Degenerative Cervical Myelopathy: The RECEDE Myelopathy Trial

Not yet recruitingEUCTR2017-004856-41-GB

Cambridge University Hospitals NHS Foundation Trust and University of CambridgeDegenerative Cervical Myelopathy

Start: 2020-03-19Target: 362Updated: 2020-05-04